Skip to main content
Fig. 1 | Hepatology, Medicine and Policy

Fig. 1

From: Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access

Fig. 1

a shows countries covered under voluntary licensing agreements from Gilead Sciences and Bristol-Meyers Squib, while 1B shows the registration status of Sovaldi® (Gilead Sciences) and Daklinza® (Bristol-Meyers Squib) worldwide. The voluntary licensing agreements exclude some countries where the burden of hepatitis C is very high, while these drugs remain unregistered in sub-Saharan African countries and parts of Asia. (Source: http://mapcrowd.org)

Back to article page
\